



Conference Presentations  
Co-Authored by STATinMED  
Research  
**2016-2021**

- Cohen A, Sah J, Dhamane A, et al. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients using five US databases: A subgroup analysis of thrombophilia. *ISTH 2021 Hematology Conference*. Phil, PA: July 17-21, 2021.
- Dhamane AD, Keshishian A, Preib MT, et al. Burden and costs of stroke/systemic embolism and major bleeding among elderly non-valvular atrial fibrillation patients prescribed oral anticoagulants. *ISTH 2021 Hematology Conference*. Phil, PA: July 17-21, 2021.
- Preib MT, Wang Y, Mitrani-Gold FS, Sun X, Joshi AV. Treatment patterns among females with uncomplicated urinary tract infections pre- and post-issue of a Food and Drug Administration warning for fluoroquinolone-associated serious adverse events. *31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)*. July 9-12, 2021.
- Munir MB, Hlavacek P, Keshishian A, et al. Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation. *Heart Rhythm Society (HRS) 2021*. June 30: Virtual kick-off, In-person: July 28-31.
- Atwater B, Di Fusco M, Keshishian A, et al. Geographic variation in anticoagulation among Medicare beneficiaries with non-valvular atrial fibrillation in the United States. *Heart Rhythm Society (HRS) 2021*. June 30: Virtual kick-off, In-person: July 28-31.
- Russell-Smith TA, Verma S, Liu Y, et al. Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors in chronic myeloid leukemia. *European Hematology Association (EHA) Virtual 2021 Congress*. June 9, 2021.
- Smith TA, Verma S, Liu Y, et al. Retrospective real-world comparison of clinical and economic burden between first generation and second-generation tyrosine kinase Inhibitors in chronic myeloid leukemia. *2021 American Society of Clinical Oncology (ASCO) Annual Meeting*. June 4-5, 2021.
- Petri M, Naessens D, Ogbomo A, et al. Epidemiology and economic burden associated with mental health comorbidities in systemic lupus erythematosus and lupus nephritis patients. *EULAR 2021 Annual European Congress of Rheumatology*: June 2-5, 2021.
- Sah J, Teeple A, Muser E, et al. Treatment patterns of biologic agents in ulcerative colitis: A pooled study of three United States claim databases. *Digestive Disease Week (DDW) 2021*. Virtual: May 21-23, 2021.
- Teeple A, Sah J, Mallampati R, et al. Treatment patterns in biologic-experienced Crohn's disease patients using three large commercial claims databases in the United States. *Digestive Disease Week (DDW) 2021*. Virtual: May 21-23, 2021.
- Ogbomo A, Tsang Y, Jaiswal M, Mallampati R, Panjabi S. Examining the direct and indirect healthcare cost among pulmonary arterial hypertension patients. *Virtual ISPOR 2021*: May 17-20, 2021.
- Siegel CA, Seigel L, Verma S, Sruti I, Mu Q, Gupte-Singh K. Current landscape and treatments used in patients with moderate-to-severe ulcerative colitis. *Virtual ISPOR 2021*: May 17-20, 2021.

- Maughn K, Chen J, Nelson DR, Fan L, Liu Y, Rey GG. Trajectory of glycated hemoglobin over time among obese type 2 diabetes patients prescribed U-100 basal-only insulin regimens: A US administrative claims data analysis. *Virtual ISPOR 2021*: May 17-20, 2021.
- Leist T, Le H, Verma S, et al. Real world adherence, persistence, relapse and multiple sclerosis symptoms among patients treated with oral disease-modifying therapies. *Virtual ISPOR 2021*: May 17-20, 2021.
- Deitelzweig S, Sah J, Kang A, et al. Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in Medicare and Veteran Affairs. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
- Munir B, Hlavacek P, Keshishian A, et al. Underutilization of oral anticoagulant therapy among elderly patients with atrial fibrillation: Insights from the United States Medicare database. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
- Dhamane A, Ferri M, Keshishian A, et al. Direct oral anticoagulants and warfarin: Effectiveness and safety outcomes among nonvalvular atrial fibrillation patients with multimorbidity. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
- Dhamane A, Ferri M, Keshishian A, et al. Effectiveness and safety of direct oral anticoagulants among nonvalvular atrial fibrillation patients with multimorbidity. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
- Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *British Society of Haematology 2021 Annual Scientific Meeting (Virtual)*: April 25-28, 2021. (ENCORE presentation, originally presented at *European School of Haematology*)
- Gandhi K, Ray M, Borra S, et al. Prevalence and incidence of vitiligo in the United States: A real-world analysis. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.
- Ogbomo A, Tsang Y, Kariburyo F, et al. Real-world analysis of treatment patterns among hospitalized pulmonary arterial hypertension patients. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.
- Huang H, Schmerold L, Dembek C, et al. Healthcare resource utilization and costs in patients with bipolar disorder treated with lurasidone or cariprazine: A retrospective analysis of insurance claims data. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: Apr 13-16, 2021.
- Chen J, Nelson DR, Borra S, et al. Trajectory of glycated hemoglobin over time among obese type 2 diabetes patients on U-100 basal-bolus insulin regimen using real-world data. *ENDO 2021 (Endocrine Society)*. Virtual: Mar 20-23, 2021.
- Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *European School of Haematology: 2nd How to Diagnose and Treat CML / MPN*. Virtual: Feb 25-28, 2021.

- Ogbomo A, Tsang Y, Panjabi S, et al. Examining hospitalization and treatment patterns of pulmonary arterial hypertension patients with and without connective tissue disease using real-world data. *Rheumatology Winter Clinical Symposium (RWCS)*. Maui, HI: Feb 10-13, 2021.
- Siddiqui MS, Myers J, Byrne C, et al. Real-world healthcare resource utilization and costs among patients with non-alcoholic fatty liver disease are substantial and increase with advanced disease. *American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting*. San Diego, CA: Nov 13-17, 2020.
- Zhuo J, Zhang Q, Knapp K, et al. Risk factors associated with interstitial lung disease in patients with RA: Findings from a retrospective healthcare database analysis. *ACR Convergence 2020 – American College of Rheumatology All-Virtual Annual Meeting*. Nov 5-9, 2020.
- Tagawa ST, Sandin R, Sah J, et al. Treatment patterns of metastatic castration-sensitive prostate cancer: A real-world evidence study. *European Society for Medical Oncology Virtual Congress 2020*. Sept 19-21, 2020.
- Castillo JJ, Yang K, Kariburyo F, et al. Clinical and economic burden of mantle cell lymphoma in the Veterans Health Administration population. *Association of VA Hematology/Oncology (AVAHO) 2020 "Virtual" Annual Meeting*. Sept 12-13, 2020.
- Castillo JJ, Yang K, Kariburyo F, et al. Real-world evidence on treatment patterns, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the Veterans Health Administration population. *Association of VA Hematology/Oncology (AVAHO) 2020 "Virtual" Annual Meeting*. September 12-13, 2020.
- Qiu Y, Zhao R, Elpers B, et al. Prevalence and characteristics of patients receiving antifibrotic therapy for idiopathic pulmonary fibrosis. *European Respiratory Society International Congress 2020*. Vienna, Austria: Sept 5-9, 2020.
- Cohen A, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer. *European Society of Cardiology (ESC) Congress 2020*. Amsterdam, The Netherlands: Aug 29 - Sept 1, 2020.
- Huang X, Hovland S, Stange S, et al. Real world disease burden, treatment patterns, and outcomes of hospitalized patients with hepatic encephalopathy. *EASL 2020 International Liver Congress*. London, UK: Aug 27-29, 2020.
- Qiu Y, Byrne C, Tang J, et al. Use of the Fibrosis-4 score to estimate fibrosis stage for patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in retrospective real-world datasets: A targeted literature review and feasibility assessment. *EASL 2020 International Liver Congress*. London, UK: Aug 27-29, 2020.
- Muser E, Teeple A, Sah J, et al. Evaluation of inpatient and emergency room utilization and costs among Crohn's disease patients treated with biologics in three large United States commercial claims databases. *Academy Health 2020 Annual Research Meeting*. Boston, MA: Jun 13-16, 2020.
- Muser E, Teeple A, Sah J, et al. Concomitant medication utilization among Crohn's disease patients newly initiating biologic therapy from three large commercial insurance claims databases. *Academy Health 2020 Annual Research Meeting*. Boston, MA: Jun 13-16, 2020.

- Hood R, Fan L, Pollom RD, et al. Treatment patterns and outcomes before and after human regular U-500 insulin initiation in patients with type 2 diabetes previously on  $\leq 200$  units/day of insulin. *American Diabetes Association (ADA) 80th Scientific Sessions 2020*. Chicago, IL: Jun 12-16, 2020.
- Cazzetta S, Chen G, Pendarla V, et al. Economic impact of perianal fistulizing Crohn's disease in US administrative claims data. *American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting*. Boston, MA, Jun 6-10, 2020.
- Cohen JM, Pandya S, Tangirala K, et al. Treatment patterns and characteristics of patients prescribed AJOVY, Emgality, or Aimovig. *American Headache Society 62nd Annual Scientific Meeting*. San Diego, CA: Jun 4, 2020.
- Cohen JM, Pandya S, Krasenbaum LJ, et al. A real-world perspective of patients with episodic migraine or chronic migraine prescribed Ajovy in the United States. *American Headache Society 62nd Annual Scientific Meeting*. San Diego, CA: Jun 4, 2020.
- Zhuo J, Zhang Q, Knapp K, et al. Examination of interstitial lung disease in patients with rheumatoid arthritis - prevalence, time to onset, and clinical characteristics. *EULAR European Congress of Rheumatology 2020 E-Congress*. Jun 3-6, 2020.
- Bhanegaonkar A, Pandya S, Kim R, et al. IMPACT RCC Real-World Study: Economic Impact of early progression among PATients with metastatic renal cell Carcinoma treated with Tyrosine kinase inhibitors in first-line setting. *International Society of Health Economics and Outcomes Research (ISPOR) 2020 Annual Meeting*. (Virtual): May 16-20, 2020.
- Chen J, Fan L, Pollom RD, et al. Insulin-related out-of-pocket pharmacy costs before and after human regular U-500 insulin initiation via insulin pen in US patients with type 2 diabetes. *International Society of Health Economics and Outcomes Research (ISPOR) 2020 Annual Meeting*. (Virtual): May 16-20, 2020.
- Sah J, Ratiu A, Gutierrez C, et al. A novel visual tool to understand the treatment patterns among treatment-naïve psoriatic arthritis patients prescribed biologics in the US Veterans Health Administration population. *International Society of Health Economics and Outcomes Research (ISPOR) 2020 Annual Meeting*. (Virtual): May 16-20, 2020.
- Delinger R, Ratiu A, Xie L, Keshishian A. Assessment of the health care utilization and economic burden on diabetes patients with chronic kidney disease in the US Veterans Health Administration population. *International Society of Health Economics and Outcomes Research (ISPOR) 2020 Annual Meeting*. (Virtual): May 16-20, 2020.
- Sah J, Ratiu A, Gutierrez C, et al. A visual analytical approach to understanding treatment patterns among treatment-naïve rheumatoid arthritis patients with biologic use in the US Veterans Health Administration database. *International Society of Health Economics and Outcomes Research (ISPOR) 2020 Annual Meeting*. (Virtual): May 16-20, 2020.
- Delinger R, Ratiu A, Xie L, Keshishian A. Comparison of economic burden and risk of hospitalization among HIV patients with and without hepatitis B coinfection in the Veterans Health Administration population. *International Society of Health Economics and Outcomes Research (ISPOR) 2020 Annual Meeting*. (Virtual): May 16-20, 2020.
- Li J, Chen CC, Janjan N, Claxton A. Assessment of economic burden and hospitalization on patients with post-traumatic stress disorder in the US Veterans Health Administration population. *International Society of Health Economics and Outcomes Research (ISPOR) 2020 Annual Meeting*. (Virtual): May 16-20, 2020.

- Muser E, Obando C, Teeple A, et al. Evaluation of biologic treatment patterns among Crohn's disease patients using three large United States claims databases. *Digestive Disease Week (DDW) Annual Meeting 2020*. Chicago, IL: May 2-5, 2020.
- Palevsky HI, Pruett J, Ogbomo A, et al. Examining titration patterns for selexipag in real-world practice using US specialty pharmacy data. *Academy of Managed Care Pharmacy (AMCP) 2020 Annual Meeting*. (Virtual): Apr 21-24, 2020.
- Delinger R, Keshishian A, Li J, et al. Assessment of economic burden and hospitalization on patients with human immunodeficiency virus in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) 2020 Annual Meeting*. (Virtual): Apr 21-24, 2020.
- Gutierrez C, Wang H, Sah J, et al. Evaluating the economic burden and hospitalization among patients with inflammatory bowel disease in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) 2020 Annual Meeting*. (Virtual): Apr 21-24, 2020.
- Shu FI, Treadwell M, Borra S, et al. Hereditary angioedema and pregnancy complications and outcomes in a population-based cohort. *American Academy of Allergy Asthma & Immunology (AAAAI) 2020 Annual Meeting*. Philadelphia, PA: Mar 13-16, 2020.
- George D, Tagawa S, Lechpammer S, et al. Overall survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving bicalutamide followed by enzalutamide or abiraterone. *American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2020*. San Francisco, CA: Feb 13-15, 2020.
- Cohen AT, Keshishian A, Lee T, et al. Safety and effectiveness of apixaban compared to warfarin among venous thromboembolism patients with active cancer: A retrospective analysis using four US claims databases. *61st American Society of Hematology (ASH) Annual Meeting and Exposition*. Orlando, FL: Dec 7-10, 2019.
- Levy M, Xie L, Wang Y, et al. Major adverse cardiac, arterial occlusive, and venous occlusive events among chronic myeloid leukemia patients prescribed ponatinib vs bosutinib in a real-world setting. *61st ASH Annual Meeting and Exposition*. Orlando, FL: Dec 7-10, 2019.
- Cohen AT, Keshishian A, Lee T, et al. Safety and effectiveness of apixaban, LMWH and warfarin among venous thromboembolism patients with active cancer: A subgroup analysis of VTE risk scale. *61st ASH Annual Meeting and Exposition*. Orlando, FL: Dec 7-10, 2019.
- Keshishian A, Wiederkehr D, Li X, et al. Patterns of oral anticoagulant treatment among non-valvular atrial fibrillation patients with end-stage renal disease treated with dialysis. *American Heart Association (AHA) Scientific Sessions*. Philadelphia, PA: Nov 16-18, 2019.
- Bhanegaonkar A, Kim R, Pandya S, et al. Real-world treatment patterns among patients with metastatic renal cell carcinoma receiving first-line therapy in the United States veteran population. *18th International Kidney Cancer Symposium (IKCS)*. Miami, FL: Nov 15-16, 2019.
- Phatak H, Zheng Y, Bhanegaonkar A, et al. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving first-line therapy in the US veteran population. *18th International Kidney Cancer Symposium (IKCS)*. Miami, FL: Nov 15-16, 2019.

- Nicholls C, Wang Y, Westerbacka J, et al. Examining the temporal trends in hypoglycemia events, treatment adherence and A1c in patients with T2D in the US. *ISPOR Annual European Congress*. Copenhagen, Denmark: Nov 2-6, 2019.
- Huang Q, Ellis L, Wang L, Shrestha S, Sundaram M. Real-world evidence of ibrutinib use among patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma in the US Veteran Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Nexus 2019*. National Harbor, MD: Oct 29 - Nov 1, 2019.
- Shrestha S, Wang L, Chen G, et al. Development and validation of an administrative claims-based inflammatory bowel disease severity index. *Academy of Managed Care Pharmacy (AMCP) Nexus 2019*. National Harbor, MD: Oct 29 – Nov 1, 2019.
- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in obese patients with nonvalvular atrial fibrillation: ARISTOPHANES subgroup analysis. *14th Annual Cardiometabolic Health Congress*. Chicago, IL: Oct 10-13, 2019.
- Patel C, Huang A, Wang L, et al. Journey of Veteran Health Administration population with recent schizophrenia diagnosis: A real-world analysis of treatment patterns and healthcare burden. *32nd Annual Psych Congress*. San Diego, CA: Oct 3-6, 2019.
- Ng-Mak D, Kadakia A, Shrestha S, et al. Hospitalization risk in pediatric bipolar patients treated with lurasidone vs other oral atypical antipsychotics: A real-world retrospective claims database study. *32nd Annual Psych Congress*. San Diego, CA: Oct 3-6, 2019.
- Kambhampati S, Parasuraman S, Yu J, et al. Hematocrit levels and thrombotic events among US veterans with polycythemia vera. *Association of VA Hematology/Oncology (AVAHO) Annual Meeting 2019*. Minneapolis, MN: Sept 20-22, 2019.
- Huang Q, Ellis L, Wang L, et al. First-line ibrutinib treatment is associated with longer time to next treatment in a real-world US veterans population. *Society of Hematologic Oncology (SOHO) 2019 Annual Meeting*. Houston, TX: Sept 11-14, 2019.
- Deitelzweig S, Keshishian A, Kang A, et al. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: An analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: Aug 31 - Sept 1, 2019.
- Deitelzweig S, Keshishian A, Kang A, et al. Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: An ARISTOPHANES study analysis. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: Aug 31 - Sept 1, 2019.
- Keshishian A, Lee T, Wygant G, et al. Patterns of extended apixaban treatment for unprovoked venous thromboembolism in routine clinical practice. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: Aug 31 - September 1, 2019.
- Neslusan C, Huang A, John J, et al. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *2019 VA/DoD Suicide Prevention Conference*. Nashville, TN: Aug 26-29, 2019.
- Keshishian A, Lee T, Wygant G, et al. Anticoagulant treatment patterns among venous thrombosis patients with active cancer: A retrospective analysis using four US claims databases. *27th International Society on Thrombosis and Hemostasis (ISTH) Congress and 65th Annual Scientific Meeting 2019*. Melbourne, Australia: Jul 6-10, 2019.

- Xie L, Kariburyo F, Sah J, et al. Real world medication use in incident systemic lupus erythematosus and lupus nephritis patients. *European Congress of Rheumatology (EULAR) 2019*. Madrid, Spain: Jun 12-15, 2019.
- Neslusan C, Sheehan JJ, Wang L, Huang A. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *American Society of Health-System Pharmacists (ASHP) Summer Meetings & Exhibition*. Boston, MA: Jun 8-12, 2019.
- Chen J, Fan L, Juneja R, et al. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen in US veterans with type 2 diabetes. *American Diabetes Association (ADA) 79th Scientific Sessions*. San Francisco, CA: Jun 7-11, 2019.
- Zheng Y, Pandya S, Yu T, et al. Real-world clinical and economic outcomes among newly-diagnosed merkel cell carcinoma patients starting checkpoint inhibitors or chemotherapy in the Veterans Health Administration. *American Society of Clinical Oncology (ASCO) 2019 Annual Meeting*. Chicago, IL: May 31 - Jun 4, 2019.
- Mavros P, Patel C, El Khoury A, et al. A real-world analysis of outcomes related to veterans with schizophrenia who transitioned to once-every-3-months paliperidone palmitate vs those who remained on once-monthly paliperidone palmitate. *American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2019*. Scottsdale, AZ: May 28-31, 2019.
- Neslusan C, Sheehan J, Wang L, Huang A. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *American Psychiatric Association (APA) Annual Meeting*. San Francisco, CA: May 18-22, 2019.
- Samuelson C, Lim J, Golembesky AK, et al. Retrospective claims analysis of treatment duration, healthcare resource utilization and costs associated with first-line treatment of NSCLC with afatinib vs erlotinib in the United States. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Pan X, Chen CC, Wang L, et al. Real-world evidence of the economic burden and risk factors for hospitalization among patients with myeloma in the US Veterans Health Administration population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Pennock G, Wang L, Pandya S. Real-world treatment patterns among metastatic renal cell carcinoma patients receiving first-line therapy in the United States veteran population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Lim S, Johnston S, Wang Y, et al. Evaluation of clinical and economic outcomes associated with staple line buttress among patients undergoing sleeve gastrectomy. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Zhang Q, Delinger R, Wang H, et al. Assessing the risk factors of heart failure among patients in the US Department of Defense population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Dieyi C, Pedarla V, Gu Y, et al. Assessing the economic burden and hospitalization among patients with non-alcoholic steatohepatitis in the US Veterans Health Administration population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.



- Wang H, Qiang W, Delinger R, et al. Examining the risk factors of chronic obstructive pulmonary disease among patients in the Department of Defense population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Okunowo O, Li L, Pedarla V, et al. Assessing the economic burden and predictors of hospitalization among US veteran patients with rheumatoid arthritis: A retrospective case-control study. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Bhanegaonkar A, Kim R, Pandya S, et al. Real-world treatment patterns among metastatic urothelial cancer patients receiving second-line therapy in the US veteran population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- Obando C, Ding Z, Muser E, et al. Evaluation of ustekinumab treatment patterns among Crohn's disease patients in three large US commercial claims databases. *Digestive Disease Week (DDW)*. San Diego, CA: May 18-21, 2019.
- Obando C, Ding Z, Muser E, et al. Evaluation of health care utilization, hospitalization/emergency room costs, and other medication use among Crohn's disease patients using ustekinumab in three large United States commercial claims databases. *Digestive Disease Week (DDW)*. San Diego, CA: May 18-21, 2019.
- Cole M, Lickert C, Drake W, et al. Baseline demographics and clinical characteristics of chronic thromboembolic pulmonary hypertension patients within the Medicare population. *American Thoracic Society (ATS) International Conference 2019*. Dallas, TX: May 17-22, 2019.
- Wang Y, Zhang Q, Xie L, et al. Overuse of short-acting bronchodilators and the risk of exacerbation among patients with chronic obstructive pulmonary disease (COPD) treated with nebulized short-acting bronchodilators. *American Thoracic Society (ATS) International Conference 2019*. Dallas, TX: May 17-22, 2019.
- Thieffry S, Borghs S, Wang L, et al. Characteristics, healthcare resource use and costs of overall pediatric focal epilepsy population and by comorbidity subgroup: A US claims database analysis. *71st American Academy of Neurology (AAN) Annual Meeting*. Philadelphia, PA: May 4-10, 2019.
- Keshishian A, Li X, Hamilton M, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: The dose subgroup analysis of the ARISTOPHANES study. *71st American Academy of Neurology (AAN) Annual Meeting*. Philadelphia, PA: May 4-10, 2019.
- Ramaswamy K, Lechpammer S, Mardekian J, et al. Survival rates and economic outcomes in chemotherapy-naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. *2019 Annual Meeting of the American Urological Association (AUA) Education and Research Inc*. Chicago, IL: May 3-6, 2019.
- Freedland SJ, Ramaswamy K, Lechpammer S, et al. Impact of prostate specific antigen doubling time on metastasis and increased costs associated with progression to metastatic castrate-resistant prostate cancer. *2019 Annual Meeting of the American Urological Association (AUA) Education and Research Inc*. Chicago, IL: May 3-6, 2019.
- Xie L, Kariburyo F, Sah J, et al. Real world medication use in Incident systemic lupus erythematosus and lupus nephritis patients. *Congress of Clinical Rheumatology – East 2019*. Destin, FL: May 2-5, 2019.

- Patel C, El Khoury A, Huang A, et al. A real-world analysis of transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate among veterans with schizophrenia. *22nd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP)*. Salt Lake City, UT: Apr 7-10, 2019.
- Hlavacek P, Guo JD, Rosenblatt L, et al. Effectiveness and safety of apixaban compared to warfarin among VTE patients in the US Medicare population. *American Heart Association (AHA) QCOR 2019*. Arlington, VA: Apr 5-6, 2019.
- El Khoury A, Patel C, Huang A, et al. Real-world outcomes among veterans severely affected by schizophrenia that transitioned from oral risperidone or paliperidone to once-monthly paliperidone palmitate. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: Mar 25-28, 2019.
- Hlavacek P, Guo JD, Rosenblatt L, et al. Comparison of costs among VTE patients initiating apixaban or warfarin in the US Medicare population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: Mar 25-28, 2019.
- Pedarla V, Gu Y, Wang L, Baser O. Health care utilization and economic burden of type-2 diabetes among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: Mar 25-28, 2019.
- Zhang Q, Delinger R, Fang B, et al. Health care utilization and economic burden of multiple myeloma among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: Mar 25-28, 2019.
- Qiang W, Fang B, Delinger R, et al. Health care utilization and economic burden of type-2 diabetes among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: Mar 25-28, 2019.
- Pedarla V, Gu Y, Wang L, Baser O. Assessing economic burden and hospitalization among asthma patients in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: Mar 25-28, 2019.
- Pavilack M, Narendranath E, Andritsos L, et al. Healthcare costs and resource utilization associated with adverse events among hairy cell leukemia patients treated with purine nucleoside analogs. *National Comprehensive Cancer Network (NCCN) 2019 Annual Conference*. Orlando, FL: Mar 21-23, 2019.
- Chowdhury R, Franchino-Elder J, Wang L, et al. Health care resource utilization and expenditures among newly diagnosed non-valvular atrial fibrillation patients initiating oral anticoagulants: Results from 100% Medicare 2010-2015 data. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: Mar 16-18, 2019.
- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in obese non-valvular atrial fibrillation patients: A pooled claims database analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: Mar 16-18, 2019.
- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in obese patients with non-valvular atrial fibrillation: ARISTOPHANES subgroup analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: Mar 16-18, 2019.

- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in obese patients with nonvalvular atrial fibrillation: ARISTOPHANES subgroup analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: Mar 16-18, 2019.
- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in obese nonvalvular atrial fibrillation patients: A pooled claims database analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: Mar 16-18, 2019.
- Lip GYH, Keshishian A, Kang A, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants among frail nonvalvular atrial fibrillation patients. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: Mar 16-18, 2019.
- Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants compared to warfarin among frail nonvalvular atrial fibrillation patients. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: Mar 16-18, 2019.
- Parasuraman S, Yu J, Paranagama D, et al. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *European School of Haematology: How to Diagnose and Treat CML/MPN*. Saggart, Ireland: Mar 8-10, 2019.
- Armstrong AW, Gadkari A, Mallya UG, et al. The economic burden associated with time to therapy escalation for patients with atopic dermatitis uncontrolled with topical therapies. *American Academy of Dermatology (AAD) Annual Meeting*. Washington, DC: Mar 1-5, 2019.
- Freedland SJ, Ramaswamy K, Lechpammer S, et al. Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients. *American Society of Clinical Oncology-Genitourinary Cancers Symposium (ASCO-GU)*. San Francisco, CA: Feb 14-16, 2019.
- Zheng Y, Pandya S, Yu T, et al. Emerging treatment patterns and checkpoint inhibitor use among newly-diagnosed merkel cell carcinoma patients in the US veteran population. *American Society of Clinical Oncology ASCO-SITC Clinical Immuno-Oncology Symposium*. San Francisco, CA: Feb 8 - Mar 2, 2019.
- Dahhan T, Cole M, Lickert C, et al. Baseline demographics and clinical characteristics of chronic thromboembolic pulmonary hypertension patients within the Medicare population. *13th Pulmonary Vascular Research Institute (PVRI) Annual World Congress on Pulmonary Vascular Disease (PVD)*. Barcelona, Spain: Jan 30 - Feb 3, 2019.
- Pandya S, Clancy Z, Shrestha S, et al. Burden of CRAB events by relapse in patients with newly diagnosed multiple myeloma not eligible for stem cell transplant. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.
- Parasuraman S, Baser O, Sturm D, et al. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.
- Levy M, Xie L, Wang Y, et al. Real-world comparisons of cardiovascular events between different tyrosine kinase inhibitors among patients with chronic myeloid leukemia. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.

- Epperla N, Pavilack M, Olufade T, et al. Adverse events among patients with hairy cell leukemia treated with purine nucleoside analogs in the United States. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.
- Lip GHY, Keshishian A, Li X, et al. Non-vitamin K antagonist oral anticoagulants associated with lower stroke rates compared to warfarin among very elderly patients with non-valvular atrial fibrillation: An ARISTOPHANES subgroup analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
- Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants among very elderly patients with non-valvular atrial fibrillation: An observational study. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
- Deitelzweig S, Keshishian A, Li X, et al. Effectiveness and safety of novel oral anticoagulants among patients with nonvalvular atrial fibrillation and diabetes: A pooled claims database analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
- Deitelzweig S, Keshishian A, Li X, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin among patients with non-valvular atrial fibrillation and diabetes: ARISTOPHANES diabetes subgroup analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
- Xie L, Sun X, Mallampati R, et al. Healthcare utilization and economic burden on patients with bladder cancer in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018*. Barcelona, Spain: Nov 10-14, 2018.
- Borra S, Lin C, Wang L, et al. Assessing the economic burden and 30-day readmission rates among patients with bladder cancer in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018*. Barcelona, Spain: Nov 10-14, 2018.
- Patel C, El Khoury A, Huang A, et al. Outcomes related to transition to once-every-three-monthly paliperidone palmitate among veterans with schizophrenia. *US Psych Congress 2018*. Orlando, FL: Oct 25-28, 2018.
- Szukis H, Benson C, Huang A, et al. Economic burden of illness among US veterans with treatment-resistant depression. *US Psych Congress 2018*. Orlando, FL: Oct 25-28, 2018.
- Ramaswamy K, Mardekian J, Schultz N, et al. Economic burden of chemotherapy naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide in the United States. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.
- George D, Schultz N, Huang A, et al. Increased costs associated with progression to metastatic castrate-resistant prostate cancer. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.
- Amin A, Keshishian A, Dina O, et al. Elderly patients with non-valvular atrial fibrillation incurred lower all-cause, stroke, and major bleeding-related costs when treated with apixaban versus dabigatran, rivaroxaban, and warfarin treatment. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.

- Amin A, Keshishian A, Dina O, et al. Healthcare costs of direct oral anticoagulants vs warfarin among Medicare patients with non-valvular atrial fibrillation. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.
- Xie L, Kariburyo F, Sah J, et al. Real-world medication use in incident systemic lupus erythematosus and lupus nephritis patients. *American College of Rheumatology (ACR) / ARHP Annual Meeting*. Chicago, IL: Oct 19-24, 2018.
- Katz NP, Gandhi K, Wei W, et al. Assessing inappropriate pain management in adults with hip or knee osteoarthritis treated with different opioid intensity regimens: Results from a retrospective database analysis. *American College of Rheumatology (ACR) / ARHP Annual Meeting*. Chicago, IL: Oct 19-24, 2018.
- Bhor M, Xie L, Arcona S, et al. Rate of vaso-occlusive crisis episodes among sickle cell disease patients in the US Medicaid population. *Sickle Cell Disease Association of America (SCDAA) 46th Annual National Convention for Sickle Cell Disease*. Baltimore, MD: Oct 10-13, 2018.
- Bhor M, Xie L, Paulose J, et al. Primary reasons for sickle-cell disease-related hospital and emergency room visits in the US Medicaid population. *Sickle Cell Disease Association of America (SCDAA) 46th Annual National Convention for Sickle Cell Disease*. Baltimore, MD: Oct 10-13, 2018.
- Pandya S, Shrestha S, Wang L, et al. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma patients. *2018 American Society of Clinical Oncology (ASCO) Quality Care Symposium*. Phoenix, AZ: Sept 28-29, 2018.
- Katz NP, Wei W, Gandhi K, et al. A real-world study of treatment regimen failure by opioid use intensity among patients with hip and/or knee osteoarthritis. *International Association for the Study of Pain (IASP) The 17th World Congress on Pain*. Boston, MA: Sept 12-16, 2018.
- Amin A, Bassalobre Garcia A, Li X, et al. Comparison of effectiveness, safety, and healthcare costs in nonvalvular atrial fibrillation patients with heart failure prescribed direct oral anticoagulants. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Amin A, Bassalobre Garcia A, Li X, et al. Comparison of effectiveness, safety, and healthcare costs of direct oral anticoagulants with warfarin in non-valvular atrial fibrillation patients with heart failure. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Amin A, Keshishian A, Zhang Q, et al. Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Deitelzweig S, Keshishian A, Li X, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Lip GYH, Keshishian A, Li X, et al. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.

- Amin A, Keshishian A, Zhang Q, et al. Effectiveness, safety, and composite clinical outcomes between apixaban and other oral anticoagulants for non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Deitelzweig S, Keshishian A, Li X, et al. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Lip GYH, Keshishian A, Li X, et al. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Lopes RD, Steffel J, Di Fusco M, et al. Standard and reduced doses of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral artery disease. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Lopes RD, Steffel J, Di Fusco M, et al. Effectiveness and safety of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation according to coronary artery disease and/or peripheral artery disease. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
- Cohen J, Beaubrun A, Bashyal R, et al. Real-world persistence for newly prescribed HIV-1 treatment: Single versus multiple tablet regimen comparison. *34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)*. Prague, Czech Republic: Aug 22-26, 2018.
- Coleman CI, Herman WH, Pandya S, et al. Body weight outcomes with canagliflozin 300 mg vs glucagon-like peptide-1 receptor agonists in a real-world setting. *American Diabetes Association (ADA) 78th Scientific Sessions*. Orlando, FL: Jun 22-26, 2018.
- Rubin DT, Long MD, Keshishian A, et al. The impact of intestinal complications on healthcare costs among inflammatory bowel disease patients with anti-TNF therapies. *Digestive Disease Week (DDW)*. Washington, DC: Jun 2-5, 2018.
- Obando C, Xie L, Vaidya N, Sah J. Evaluate the treatment patterns and healthcare utilizations for biologic therapies for Crohn's disease. *Digestive Disease Week (DDW)*. Washington, DC: Jun 2-5, 2018.
- Pandya S, Clancy Z, Shrestha S, et al. Economic burden of early progression in newly-diagnosed multiple myeloma patients. *2018 American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL: Jun 1-5, 2018.
- Bhor M, Wang Y, Xie L, et al. Poor medication adherence and high rates of treatment discontinuation among SCD patients treated with hydroxyurea. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
- Xie L, Wang Y, Qiang W, et al. Health care utilization and economic burden of patients with inflammatory bowel disease in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.

- Gupta A, Lin C, Wang L, et al. Assessing the economic burden and 30-day readmission rates among patients with chronic obstructive pulmonary disease in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
- Bhor M, Wang Y, Xie L, et al. Relationship between pain crisis and life-threatening complications in sickle cell disease: A retrospective claims based study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
- Parasuraman S, Yu J, Paranagama D, et al. Hematocrit levels and thrombotic events (TEs) among US veterans with polycythemia vera. *European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasm*. Saggart, Ireland: May 15-17, 2018.
- Bhor M, Wang Y, Xie L, et al. Clinical burden and management of sickle cell disease among pediatric patients. *The 2018 American Society of Pediatric Hematology/Oncology (ASPHO) Conference*. Pittsburgh, PA: May 2-5, 2018.
- Huang A, Wei W, Gandhi K, et al. Opioid use intensity and its association with opioid overdose risk and abuse and hospitalization among patients with hip/knee osteoarthritis: A retrospective analysis of real-world data. *American Academy of Pain Medicine's (AAPM) 34th Annual Meeting*. Vancouver, Canada: April 26-29, 2018.
- Borra S, Lin C, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with breast cancer in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. Boston, MA: April 23-26, 2018.
- O'Neal W, Mendes S, Baser O, et al. Adherence and outpatient resource use with extended-release oxcarbazepine (Oxtellar XR®) vs immediate-release oxcarbazepine: Analysis of pooled data from four national claims databases. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. Boston, MA: April 23-26, 2018.
- Xie L, Baser O, Wang Y, et al. Health care utilization and economic burden on patients diagnosed with epilepsy in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. Apr 23-26, 2018: Boston, MA.
- Fishman J, Shrestha S, Wang L, et al. Impact of Medicaid antiepileptic drug formulary restrictions on health outcomes and costs. *2018 American Academy of Neurology (AAN) Annual Meeting*. Los Angeles, CA: Apr 21-27, 2018.
- Deitelzweig S, Keshishian A, Li X, et al. Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated in US clinical practice. *American College of Cardiology (ACC) 67th Annual Scientific Session & Expo*. Orlando, FL: Mar 10-12, 2018.
- Pandya S, Wang L, Baser O, et al. The burden of hypoxic respiratory failure in preemies and neonates in the United States: 2011-2015. *Hot Topics in Neonatology*. Washington, DC: Dec 11-13, 2017.
- Huntington S, Keshishian A, Xie L, et al. Real-world patterns of care for patients with follicular lymphoma treated with lenalidomide and rituximab (R2) in the US Medicare population. *American Society of Hematology (ASH) Annual Meeting*. Atlanta, GA: Dec 9-12, 2017.

- Gupta K, Mardekian J, Shank T, et al. Comparisons of all-cause, stroke- and major bleeding-related medical costs among non-valvular atrial fibrillation patients who initiated oral anticoagulation therapies in the US Department of Defense Military Health System. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
- Amin A, Keshishian A, Trocio J, et al. Risk of stroke and major bleeding for dabigatran, rivaroxaban, and warfarin compared to apixaban among non-valvular atrial fibrillation patients in the United States Medicare population. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
- Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of apixaban compared to other anticoagulants among non-valvular atrial fibrillation patients with coronary artery disease or peripheral arterial disease: A propensity score matched analysis of four large databases. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
- Deitelzweig S, Keshishian A, Li X, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban among non-valvular atrial fibrillation patients: A propensity score matched analysis of four large databases. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
- Lopes RD, Di Fusco M, Keshishian A, et al. Effectiveness and safety of apixaban versus other oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral arterial disease. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
- Xie L, Zhou FL, Pan C, et al. Impact of treatment persistence on glycated haemoglobin A1c (HbA1c) trends among patients with type 2 diabetes newly initiated on basal insulin. *53rd European Association for the Study of Diabetes Annual Meeting*. Lisbon, Portugal: Sept 11-15, 2017.
- Xie L, Zhou L, Kariburyo F, et al. Clinical outcomes of patients with type 2 diabetes who switched to insulin glargine 300 U/ml from insulin glargine 100 U/ml in real world US treatment settings. *Association of British Clinical Diabetologists (ABCD) Autumn Meeting*. London, United Kingdom: Nov 10, 2017.
- Zhang Q, Kariburyo MF, Xu J, et al. Examining health care utilization and costs among atherosclerosis patients in the US Veteran Health Administration population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.
- Vaidya N, Wang Y, Xie L, Baser O. Evaluating the economic burden and health care utilization of bacterial pneumonia in the US Department of Defense population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.
- Wang L, Lewis-Black C, Fritschel E, Baser E. Comparison of various meta-analysis techniques. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.
- Ogbomo A, Lin Y, Keshishian A, et al. A comparative analysis of the health care utilization and costs of patients diagnosed with and without liver cancer in the US Medicare population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.
- Yazici Y, Simsek I, Xie L, et al. A real-world analysis of treatment patterns in a Turkish rheumatology population with continuous infliximab therapy or switched to biosimilar infliximab. *American College of Rheumatology (ACR) 2017 Annual Meeting*. San Diego, CA: Nov 3-8, 2017.



- Nazareth T, Kariburyo F, Kirkemo A, et al. Membranous nephropathy: A real-world clinical and economic analysis. *American Society of Nephrology (ASN) Kidney Week 2017*. New Orleans, LA: Oct 31 - Nov 5, 2017.
- Nazareth T, Kariburyo F, Kirkemo A, et al. Focal segmental glomerulosclerosis: A claims analysis of clinical and economic outcomes. *American Society of Nephrology (ASN) Kidney Week 2017*. New Orleans, LA: Oct 31 - Nov 5, 2017.
- Ariely R, Chipps BE, Stoyanov S, et al. Budgetary impact model on a Medicare plan adopting short-acting beta-agonist inhalers with integrated dose counters. *2017 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology*. Boston, MA: Oct 26-30, 2017.
- Mutlu E, Ogbomo A, Goyal K, Ellis L. Real-world utilization of biosimilar and originator infliximab in a cohort of patients with inflammatory bowel disease in Turkey. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.
- Ellis L, Simsek I, Xie L, et al. Analysis of real-world treatment patterns in a matched sample of rheumatology patients with continuous infliximab therapy or switched to biosimilar infliximab. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.
- Zhou FL, Xie L, Wang Y, et al. Lower hypoglycemia risk and better persistence in adults with type 2 diabetes after switch to insulin glargine 300 U/mL vs other basal insulins in real-world clinical settings. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
- Hall E II, Wells W, Teynor M, et al. Healthcare resource utilization and costs of spinal muscular atrophy care in the US Medicaid population. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
- Kerwin EM, Stoyanov S, Wang L, et al. The budget impact on the adoption of short-acting beta-agonist inhalers with integrated dose counters in managed care. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
- Shah A, Xie L, Kariburyo F, et al. Real-world comparison of treatment patterns, health care resource utilization and costs in schizophrenia patients treated with long-acting injectable vs oral. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
- Zhao Q, Wang L, Kurlansky PA, et al. Impact of coronary artery disease on clinical outcomes among patients with newly-diagnosed heart failure with systolic dysfunction: Is it changing over time? *Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting*. Dallas, TX: Sept 16-19, 2017.
- Huang A, Amos T, Joshi K, et al. Burden of schizophrenia in recently diagnosed adult patients: A commercial payer perspective. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.
- Benson C, Huang A, Wang L, et al. Clinical and economic burden of major depressive disorder among US veterans. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.
- Shah A, Xie L, Kariburyo F, et al. Treatment patterns, healthcare resource utilization and costs in schizophrenia patients treated with long-acting injectable vs oral antipsychotics: A real-world study. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.

- Duncan M, Wang Y, Xie L, et al. Prevalence and treatment patterns of opioid use disorder in two commercial populations. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.
- Zhang Q, Xie L, Baser O, McGuire M. Evaluating treatment patterns of relapsed acute myeloid leukemia among the elderly in the United States. *Society of Hematologic Oncology (SOHO) Annual Meeting*. Houston, TX: September 13-16, 2017.
- Taylor K, Araujo AB, Wang L, et al. Effectiveness of a private, orthopedic practice-based osteoporosis management program for prevention of recurrent fractures. *American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting*. Denver, CO: Sept 8-11, 2017.
- Pandya S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with heart failure in the US Veterans Health Administration population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.
- Li X, Lip GYH, Keshishian A, et al. Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
- Li X, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
- Lip GYH, Keshishian A, Li X, et al. Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
- Amin A, Keshishian A, Trocio J, et al. Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
- Peacock WF, Coleman C, Wells P, et al. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
- Zhao Q, Wang L, Kurlansky PA, et al. Short and intermediate term all-cause mortality among newly-diagnosed heart failure patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
- Vaidya N, Xie L, Wang Y, et al. Evaluating the economic burden and health care utilization of migraine in the US Department of Defense population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.
- Ogbomo A, Keshishian A, Xie L, et al. A descriptive analysis of the health care utilization and costs of patients diagnosed with multiple myeloma in the US Medicare population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.

- Zhang Q, Xie L, Keshishian A, et al. Examining the health care utilization and costs among elderly patients with chronic obstructive pulmonary disease in the United States. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.
- Wells P, Peacock WF, Fermann GJ, et al. The value of sPESI for risk stratification in patients with pulmonary embolism. *International Society on Thrombosis and Hemostasis (ISTH) 2017*. Berlin, Germany: Jul 8-13, 2017.
- Phillips K, Juday T, Zhang Q, Keshishian A. Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed Infliximab or CT-P13 in the Turkish population. *European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology*. Madrid, Spain: Jun 14-17, 2017.
- Kuritzkes BA, Pappou EP, Guo X, et al. Visceral fat area, not body mass index, predicts postoperative 30-day morbidity in patients undergoing colon resection for cancer. *American Society of Colon and Rectal Surgeons (ASCRS) 2017 Annual Scientific and Tripartite Meeting*. Seattle, WA: Jun 10-14, 2017.
- Zhou F, Xie L, Pan C, et al. Impact of treatment persistence on A1C trends among patients with T2D newly initiated on basal insulin. *American Diabetes Association (ADA) 77th Scientific Sessions*. San Diego, California: Jun 9-13, 2017.
- Vaidya N, Tan H, Xie L, Wang Y, Baser O. Evaluating the economic burden and health care utilization of rheumatoid arthritis patients in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with pneumonia in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with clostridium difficile infection in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Xie L, Zhang Q, Baser O, McGuire M. Examining the health care resource use and economic costs associated with acute myeloid leukemia among Medicare patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Ogbomo A, Lin Y, Wang Y, et al. A descriptive analysis of the health care utilization and costs of patients diagnosed with lymphoma in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.

- Xie L, Vaidya N, Wang Y, et al. Evaluating the economic burden and health care utilization of prostate cancer patients in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Lin Y, Ogbomo A, Wang Y, et al. A descriptive analysis of the health care utilization and costs of patients diagnosed with myelodysplastic syndrome in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Du J, Xie L, Keshishian A, et al. Assessing the hospital readmission and mortality rates among elderly patients with chronic obstructive pulmonary disease. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
- Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- Ganapathy V, Xie L, Keshishian A, et al. Continuing care with nebulized bronchodilators after hospital discharge and impact on readmissions: Analysis of Medicare COPD beneficiaries receiving arformoterol vs nebulized short-acting agents. *American Thoracic Society (ATS) International Conference 2017*. Washington, DC: May 19-24, 2017.
- Black CM, Fillit H, Xie L, et al. Rates of institutionalization among newly-diagnosed Alzheimer's disease patients. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: April 22-28, 2017.
- Black CM, Fillit H, Xie L, et al. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: Apr 22-28, 2017.
- Wang L, Baser O, Wells P, et al. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *Society of General Internal Medicine (SGIM) 2017 Annual Meeting*. Washington, DC: Apr 19-22, 2017.
- Nazareth T, Kariburyo F, Pirani A, et al. Patients with nephrotic syndrome receiving repository corticotrophin injection or rituximab: Real-world evidence from a US claims analysis. *National Kidney Foundation (NKF) 2017 Spring Clinical Meetings*. Orlando, FL: Apr 18-22, 2017.
- Xie L, Parikh K, Abouzaid S, et al. Real-world treatment outcomes and costs among newly-diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide. *13th Hematology/Oncology Pharmacy Association (HOPA) Annual Conference*. Anaheim, CA: Mar 29 - Apr 1, 2017.
- Black CM, Fillit H, Xie L, et al. Rates of institutionalization among newly diagnosed Alzheimer's disease patients. *13th International Conference on Alzheimer's & Parkinson's Diseases*. Vienna, Austria: Mar 29 - Apr 2, 2017.
- Black CM, Fillit H, Xie L, et al. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *13th International Conference on Alzheimer's & Parkinson's Diseases*. Vienna, Austria: Mar 29 - Apr 2, 2017.

- Lee S, Xie L, Wang Y, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Managed Care Specialty Pharmacy Annual Meeting 2017*. Denver, CO: Mar 27-30, 2017.
- Ye F, Zhou FL, Xie L, et al. Clinical outcomes of patients with type 2 diabetes who switched to insulin glargine 300 U/mL from insulin glargine 100 U/mL in real-world US treatment settings. *Academy of Managed Care Pharmacy (AMCP) Managed Care Specialty Pharmacy Annual Meeting 2017*. Denver, CO: Mar 27-30, 2017.
- Ganapathy V, Xie L, Wang Y, et al. Prescription fill patterns after reaching the Medicare Part D coverage gap among chronic obstructive pulmonary disease patients on maintenance bronchodilators. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2017*. Denver, CO: Mar 27-30, 2017.
- Chipps B, Ferro T, Wang L, et al. Healthcare costs in asthma and/or chronic obstructive pulmonary disease patients using albuterol inhalation aerosol with and without an integrated dose counter. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2017*. Denver, CO: Mar 27-30, 2017.
- Pandya S, Abouzaid S, Xie L, et al. Real-world health care costs among newly-diagnosed multiple myeloma patients in the United States veteran population (FY 2011-2015). *National Comprehensive Cancer Network (NCCN) 22nd Annual Conference*. Orlando, FL: Mar 23-25, 2017.
- Amin A, Keshishian A, Vo L, et al. Real-world comparison of major bleeding and associated costs among oral anticoagulant-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population. *American College of Cardiology (ACC) 66th Annual Scientific Session & Expo*. Washington, DC: Mar 17-19, 2017.
- Amin A, Keshishian A, Trocio J, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the US Medicare population. *American College of Cardiology (ACC) 66th Annual Scientific Session & Expo*. Washington, DC: Mar 17-19, 2017.
- Ganapathy V, Xie L, Wang Y, et al. Hospital readmissions among chronic obstructive pulmonary disease patients treated in skilled nursing facilities in the US. *AMDA (Society for Post-acute and Long-term Care Medicine) Annual Conference 2017*. Phoenix, AZ: Mar 16-19, 2017.
- Lee S, Xie L, Wang Y, Baser O. Evaluating the economic burden and incidence of comorbidities among moderate-to-severe PsO and/or PsA patients in the US Department of Defense population. *American Academy of Dermatology (AAD) 2017 Annual Meeting*. Orlando, FL: Mar 3-7, 2017.
- Shrestha S, Baser O, Zhou X, Kwong WJ. Inappropriate dosing of oral anticoagulants among patients with non-valvular atrial fibrillation. *American Heart Association (AHA) International Stroke Conference (ISC) 2017*. Houston, TX: Feb 22-24, 2017.
- Sonpavde G, Huang A, Wang L, et al. First-line chemotherapy (CT) versus anti-androgen therapy for patients with metastatic castration-resistant prostate cancer: Individual patient analysis of the Veterans Health Administration (VHA) dataset. *2017 Genitourinary Cancers Symposium*. Orlando, FL: Feb 16-18, 2017.

- Ganapathy V, Xie L, Wang Y, et al. Time to reach coverage gap and catastrophic coverage: A Medicare Part D claims analysis among beneficiaries with chronic obstructive pulmonary disease. *American Society of Health-System Pharmacists (ASHP) 2016 Midyear Clinical Meeting*. Las Vegas, NV: Dec 4-8, 2016.
- Peacock F, Baser O, Kohn C, et al. External validation of a clinical and claims-based approach for predicting 90-day post-pulmonary embolism outcomes among US veterans. *American Society of Hematology (ASH) 58th Annual Meeting & Exposition*. San Diego, CA: Dec 3-6, 2016.
- Huntington S, Keshishian A, Xie L, et al. Evaluating the economic burden and health care utilization following first-line therapy for diffuse large B-cell lymphoma patients in the US Medicare population. *American Society of Hematology (ASH) 58th Annual Meeting & Exposition*. San Diego, CA: Dec 3-6, 2016.
- Parikh K, Pandya S, Abouzaid S, et al. Real world treatment outcomes and cost among newly-diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide. *American Society of Hematology (ASH) 58th Annual Meeting & Exposition*. San Diego, CA: Dec 3-6, 2016.
- Copher R, Wang L, Wang J, Cavazos J. Racial differences in the incidence and prevalence of epilepsy in United States veteran population. *American Epilepsy Society (AES) Annual Meeting*. Houston, TX: Dec 2-6, 2016.
- Wang L, Baser O, Wells P, et al. Effectiveness of rivaroxaban among patients diagnosed with pulmonary embolism. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: Nov 12-16, 2016.
- Wang L, Baser O, Wells P, et al. Benefit of early discharge among patients with low-risk pulmonary embolism: Focus on net clinical impact. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: Nov 12-16, 2016.
- Amin A, Keshishian A, Vo L, et al. Real-world comparisons of major bleeding risk for commercially insured non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: Nov 12-16, 2016.
- Lip GYH, Keshishian A, Kamble S, et al. Real world comparisons of major bleeding risk stratified by CHA<sub>2</sub>DS<sub>2</sub>-VASc scores among non-valvular atrial fibrillation patients initiating apixaban or warfarin. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: Nov 12-16, 2016.
- Yazici Y, Xie L, Ogbomo A, et al. A descriptive analysis of real-world treatment patterns of innovator infliximab (Remicade) and biosimilar infliximab in a treatment naïve Turkish rheumatologic disease population. *American College of Rheumatology (ACR)/ARHP Annual Meeting*. Washington, DC: Nov 11-16, 2016.
- Shrestha S, Miao R, Wang L, et al. Burden of atopic dermatitis among adults in a state Medicaid program (Medi-Cal). *American College of Allergy, Asthma & Immunology (ACAAI) 2016 Annual Scientific Meeting*. San Francisco, CA: Nov 10-14, 2016.
- Wang L, Li L, Zhou X, Pandya S, Baser O. Evaluation of the clinical characteristics and economic burden of United States veteran patients diagnosed with the hepatitis C virus. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: Oct 29 - Nov 2, 2016.

- Wang L, Li L, Pandya S, Baser O. Evaluating socio-demographic characteristics of patients in the United States Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Congress 2016*. Vienna, Austria: Oct 29 - Nov 2, 2016.
- Wang L, Li L, Zhou X, Pandya S, Baser O. Assessing the clinical and economic burden of prostate cancer in the United States veteran population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: Oct 29 - Nov 2, 2016.
- Xie L, Zhang Q, Xin K, et al. Health care utilization and economic burden of pancreatic cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: Oct 29 - Nov 2, 2016.
- Xie L, Vaidya N, Xin K, et al. Evaluating the economic burden and health care utilization of lung cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: Oct 29 - Nov 2, 2016.
- Xie L, Vaidya N, Xin K, et al. Evaluating the economic burden and health care utilization of breast cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: Oct 29 - Nov 2, 2016.
- Wang L, Li L, Pandya S, Baser O. A real-world evaluation of the clinical and economic burden of United States veteran patients with post-traumatic stress disorder. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: Oct 29 - Nov 2, 2016.
- Wang L, Sung A, Marcella S, Mohamed O. Burden of clostridium difficile infection (CDI) across hospital inpatient, nursing home, and home settings. *Infectious Diseases Society of America (IDSA) Infectious Disease Week (IDWeek)*. New Orleans, LA: Oct 26-30, 2016.
- Amin A, Keshishian A, Vo L, et al. Real-world comparison of major bleeding and associated costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *Academy of Managed Care Pharmacy (AMCP) Nexus*. National Harbor, MD: Oct 3-6, 2016.
- Yazici Y, Simsek I, Xie L, et al. A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab. *Academy of Managed Care Pharmacy (AMCP) Nexus*. National Harbor, MD: Oct 3-6, 2016.
- Xie L, Zhou S, Kariburyo F, et al. Clinical and economic outcomes in patients with type 2 diabetes switching from basal insulin plus rapid-acting insulin to basal insulin plus glucagon-like peptide-1: A real-world observational study. *Academy of Managed Care Pharmacy (AMCP) Nexus*. National Harbor, MD: Oct 3-6, 2016.
- Parasuraman S, Yu J, Paranagama D, et al. Demographic and clinical characteristics of patients with polycythemia vera (PV) in the US veterans population. *Association of VA Hematology/Oncology (AVAHO) 12th Annual Meeting*. Dallas, TX: Sept 23-25, 2016.
- Parikh K, Pandya S, Abouzaid S, et al. Treatment patterns among newly diagnosed multiple myeloma patients in the United States Veteran Population (2010-2015). *2016 ASH Meeting on Hematologic Malignancies*. Chicago, IL: Sept 16-17, 2016.

- Lip GYH, Keshishian A, Shital K, et al. Major bleeding risk in patients aged 75 years or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: Aug 27-31, 2016.
- Kamble S, Keshishian A, Pan X, et al. Real-world comparisons of major bleeding risk and associated hospitalization costs among elderly non-valvular atrial fibrillation patients newly initiated on apixaban or warfarin. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: Aug 27-31, 2016.
- Lip GYH, Keshishian A, Kamble S, et al. Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: Aug 27-31, 2016.
- Amin A, Keshishian A, Xie L, et al. Real-world comparison of major bleeding and associated costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban or warfarin. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: Aug 27-31, 2016.
- Cole A, Shrestha S, Baser E. Prevalence of Crigler-Najjar in the Turkish Population. *32nd International Conference for Pharmacoepidemiology (ICPE/ISPE)*. Dublin, Ireland: Aug 25-28, 2016.
- Black CM, Hu X, Khandker RK, et al. Comparison of all-cause mortality rate and economic burden between newly diagnosed Alzheimer's disease patients who received anti-dementia treatment versus not: A longitudinal retrospective study. *Alzheimer's Association International Conference (AAIC) Annual Conference*. Toronto, Canada: Jul 24-28, 2016.
- Cai J, Wang Y, Baser O, et al. Comparative persistence with antihyperglycemic agents used to treat type 2 diabetes mellitus in the real world. *American Diabetes Association (ADA) 76th Scientific Sessions*. New Orleans, LA: Jun 10-14, 2016.
- Wei W, Knapp K, Wang L, et al. Real-world treatment persistence and clinical outcomes of TNFi cycling vs switching to new mechanism of action DMARDs among patients with rheumatoid arthritis in the United States. *2016 European League Against Rheumatism (EULAR) Annual Congress*. London, United Kingdom: Jun 8-11, 2016.
- Ogbomo A, Zhao Y, Kariburyo MF, et al. Retrospective analysis of the economic burden of patients diagnosed with congestive heart failure in the California Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Pandya S, Du H, Wang L, et al. Mortality and rehospitalization rates among hospitalized congestive heart failure patients in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Bashyal R, Du H, Wang L, et al. Examining the mortality and readmission rates of patients diagnosed with stroke in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Keshishian A, Du J, Xie L, et al. Demographic and socioeconomic characteristics that impact selection of oral anticoagulants among non-valvular atrial fibrillation patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.



- Zhang Q, Zhao Y, Keshishian A, et al. Evaluating the economic burden and health care utilization of coronary artery disease in the US Medi-Cal population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Keshishian A, Tan H, Xie L, Baser O. Examination of the economic burden of dyslipidemia in the Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Kariburyo F, Du J, Xie L, Baser O. Assessing the economic burden of rheumatoid arthritis patients with different clinical disease activity index scores: a probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Kariburyo F, Du J, Xie L, Baser O. Examining the health care resource utilization and economic burden among rheumatoid arthritis patients with different routine assessment of patient index data 3 scores: A probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Pesa JA, Wang L, Yuce H, Baser O. Proton pump inhibitor utilization among patients with hepatitis C virus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Cheng E, Wang L, Morgenstern D, et al. Healthcare costs among men with clinically localized prostate cancer managed with observation strategies versus immediate treatment in an integrated health care system. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Tan H, Xie L, Baser O, et al. Evaluating the economic burden and health care utilization of anemia in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Tan H, Xie L, Wang Y, et al. Examine the burden of illness of US Medicare patients diagnosed with cataract. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Zhang Q, Zhao Y, Keshishian A, Xie L, et al. Comparing health care resource utilization and costs among obese patients in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of alcohol dependence among US veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with drug dependence in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.

- Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of bipolar disorder among US veteran patients from 2011 to 2015. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with depressive disorder in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Bashyal R, Du H, Wang L, et al. Mortality and prevalence of major depressive disorder in the US Medicare population from 2008-2013. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Zhang Q, Zhao Y, Keshishian A, et al. Assessing the economic burden and health care utilization of attention deficit/hyperactivity disorder among US Medicaid patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Zhang Q, Zhao Y, Keshishian A, et al. Evaluating asthma-related expenses and health care resource utilization among children in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Ogbomo A, Tan H, Kariburyo F, et al. Assessing the economic burden and health care resource utilization of US veterans with chronic obstructive pulmonary disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Ogbomo A, Tan H, Kariburyo F, et al. Assessing health care resource utilization and costs among US veterans diagnosed with asthma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Pandya S, Du H, Wang L, et al. Mortality and rehospitalization rates among patients with chronic obstructive pulmonary disease in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Sanon M, Xie L, Bent-Ennakhil N, et al. Health care utilization and costs in treated and non-treated US patients newly diagnosed with Alzheimer's disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Teeple A, Kariburyo MF, Ingham M, et al. Differences between patient and physician perspectives toward starting biologics: Stratification by minority patient response vs white/undetermined patient response. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- Xie L, Ingham M, Kariburyo F, et al. The classification and regression tree approach to predicting patient-specific factors associated with discussing biologic treatment with a health care provider in Crohn's disease patients. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: Apr 19-22, 2016.

- Xie L, Ingham M, Kariburyo F, et al. Differences between patient and physician perspectives toward starting biologics: Stratification by patients who had a discussion about biologics with their physician vs those who did not. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: Apr 19-22, 2016.
- Agashivala N, Keshishian A, Xie L, Greenberg S. Health care resource utilization and costs among patients diagnosed with sporadic inclusion body myositis in the US Medicare population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: Apr 19-22, 2016.
- Pesa JA, Doshi D, Wang L, Baser O. Description of health care utilization and costs among young, recently diagnosed schizophrenia patients one year prior to treatment with paliperidone palmitate once monthly injectable. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: Apr 19-22, 2016.
- Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, warfarin, dabigatran or rivaroxaban: A 1:1 propensity-score matched analysis. *American College of Cardiology (ACC) 65th Annual Scientific Session & Expo*. San Diego, CA: Apr 2-4, 2016.
- Amin A, Keshishian A, Xie L, et al. Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American College of Cardiology (ACC) 65th Annual Scientific Session & Expo*. San Diego, CA: Apr 2-4, 2016.
- Quek RGW, Fox KM, Wang L, et al. Increased incidence of cardiovascular disease events among diabetes patients with complications. *American Heart Association (AHA) Epidemiology and Prevention (EPI) / Lifestyle and Cardiometabolic Health 2016 Scientific Sessions*. Phoenix, AZ: Mar 1-6, 2016.